Case Report

Atypical Manifestation of DRESS Syndrome

Christopher Hakim, Constantine Melitas, Eric Nguyen, and Kha Ngo

1Department of Internal Medicine, Ascension Providence Hospital, Michigan State University College of Human Medicine, Southfield, USA
2Department of Gastroenterology, Ascension Providence Hospital, Michigan State University College of Human Medicine, Southfield, USA
3American University of the Caribbean School of Medicine, Coral Gables, USA

Correspondence should be addressed to Christopher Hakim; cmhak@msu.edu

Received 4 December 2019; Accepted 19 March 2020; Published 13 April 2020

Academic Editor: Yoshihiro Moriwaki

Copyright © 2020 Christopher Hakim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pj_hedifferentialforlivertransaminasesover1000units/litertypicallyincludesliverischemia,acuteviralhepatitis,acetaminophentoxicity,andautoimmunehepatitis.Promptevaluationisimperativeredasetheseetiologiescanleadtofulminantliverfailure.Wepresentacaseoftransaminasesover1000units/literfromanatypicaletiology.A52-year-oldmale,previouslytreatedwithallopurinolforanacutegoutflare,presentedwithpersistentfevers.Giventhathehadtakena“high-riskmedication”2–6weeksbeforepresentation,subsequentlypresentedwithfever,rash,renalimpairment,elevatedliverenzymesinthethousands,andperipheraleosinophilia,DRESSsyndromesecondarytoallopurinolwasdiagnosed.

1. Introduction

Elevated liver chemistries (LFTs) include a wide differential diagnosis, and delineating the cause is imperative for treatment. More specifically, LFTs in the thousands include a narrow differential in which assessment for acetaminophen toxicity and testing for acute viral causes, autoimmune hepatitis, ischemic hepatitis/shock liver, and vascular disorders including acute portal vein thrombosis and acute Wilsonian crisis, as well as workup for biliary obstruction, must be performed [1].

We present a case of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, which presented as a rare cause of liver enzymes in the thousands.

2. Case Report

A 52-year-old African American male presented to the emergency department from his primary care physician’s office due to persistent fever. The patient had been discharged from the hospital one week prior after being hospitalized for diarrhea due to Clostridium difficile colitis, which was treated with oral vancomycin. During that hospitalization, he was started on allopurinol for an acute gout flare after which he developed a generalized purpuric, morbilliform rash, which started on his chest and spread to his extremities. He was discharged on a prednisone taper for a suspected drug rash, which he completed prior to returning to the hospital.

His past medical history includes hypertension, chronic kidney disease stage 5, osteoarthritis, GERD, and gout. On initial examination, his temperature was 38.3°C with vitals within normal limits. Skin excoriations were noted, but no rash or lymphadenopathy. His cardiopulmonary and abdominal exams were unremarkable. Laboratory data demonstrated a white blood cell count within normal limits, hemoglobin 7.9 gm/dL, platelet count 71K/mcl, creatinine 6.4 mg/dL (baseline 5-6 mg/dL), BUN 60 mg/dL, and elevated LFTs with AST 878 units/L, ALT 1,117 units/L, alkaline phosphatase 169 units/L, and GGT 209 units/L. Of note, the patient had known anemia of chronic disease; however, his thrombocytopenia was a new occurrence. Lactic acid was normal, and urinalysis showed no signs of active urinary
DRESS syndrome is a hypersensitivity drug reaction characterized by rash, hematologic abnormalities, lymphadenopathy, and organ involvement, including liver and kidney with mortality as high as 10% [2, 3]. It has a prevalence of 2.18 per 100,000 patients with specific diagnostic criteria [4, 5]. The pathogenesis is hypothesized to be secondary to an accumulation of toxic drug metabolites due to various enzymatic deficiencies [2].

The presenting symptoms in almost all patients include skin rash, liver involvement, hypereosinophilia, and lymphadenopathy [6]. The first symptoms to present are fever and rash, as were seen in our patient prior to his admission. Skin manifestations occur as a morbilliform eruption, which involves over 50% of the body and includes two or more of the following: facial edema, infiltrative lesions, scaling, and/or purpura [6].

The liver is the most common affected organ in DRESS syndrome. Liver involvement is generally mild and infrequently causes liver chemistry elevations in the thousands with rare progression to fulminant hepatic failure [7]. Hematological findings are also commonly seen in DRESS syndrome, with eosinophilia being the most common manifestation, often delayed by 1-2 weeks [6, 8, 9]. Renal dysfunction is also commonly appreciated [8].

Allopurinol has one of the strongest associations with DRESS syndrome [10]. Other high-risk medications include carbamazepine, lamotrigine, phenytoin, and phenobarbital [5].

Diagnosing DRESS syndrome can be challenging but should be suspected in a patient who received a new high-risk medication in the previous 2–6 weeks and presents with characteristic symptoms as outlined above. Bocquet’s diagnostic criteria include the presence of three conditions such as drug-induced skin eruption, eosinophilia ≥1500/μl, and at least one of the following systemic abnormalities: lymphadenopathy, hepatitis (LFTs >2 ULN), interstitial nephropathy, interstitial lung disease, or myocardial involvement [5]. The RegisSCAR criteria for diagnosis is another diagnostic tool which classified our patient as “probable” of having DRESS syndrome [11]. Additionally, there is a Japanese diagnostic tool which has been shown to be significantly less accurate [12].

Supportive therapy and prompt withdrawal of the offending agent is the primary treatment. Most patients recover completely in weeks to months after drug withdrawal. Systemic corticosteroids are used by some; however, the literature has not shown a significant benefit [13].

In the setting of significant liver injury, administration of NAC and transfer to a liver transplant center are important considerations. NAC improves overall tissue oxygen delivery to the liver and has been shown to improve mortality. Additionally, studies have demonstrated an increase in transplant-free survival and post-liver transplant survival in several causes of nonacetaminophen acute liver injuries including drug-induced, viral, and autoimmune [14–16].

To avoid complications and death due to DRESS syndrome, prompt diagnosis with removal of the offending agent, supportive care, and administration of NAC in the setting of significant liver injury are imperative.

Consent

Informed patient consent was obtained for publication of the case details.

Disclosure

Prior presentations of this study include the following: (1) Hakim, C., Melitas, C., Nguyen, E., Ngo, K. unDRESSing elevated liver enzymes. Program No. P2547. ACG 2019 Annual Scientific Meeting Abstracts, San Antonio, Texas: American College of Gastroenterology. (2) Hakim, C., Melitas, C., Nguyen, E., Ngo, K. unDRESSing elevated liver enzymes. ACP Michigan Chapter 2019 Annual Meeting, May 3, 2019, Sterling Heights, MI.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] P. Y. Kwo, S. M. Cohen, and J. K. Lim, “ACG clinical guideline: evaluation of abnormal liver chemistries,” *American Journal of Gastroenterology*, vol. 112, no. 1, pp. 18–35, 2017.

[2] S. Choudhary, M. Mcleod, D. Torchia, and P. Romanelli, "Drug reaction with eosinophilia and systemic symptoms
(DRESS) syndrome,” The Journal of Clinical and Aesthetic Dermatology, vol. 6, no. 6, pp. 31–37, 2013.

[3] D. Seth, D. Kamat, and J. Montejo, “DRESS syndrome: a practical approach for primary care practitioners,” Clinical Pediatrics, vol. 47, no. 9, pp. 947–952, 2008.

[4] A. R. Wolfson, L. Zhou, Y. Li, N. A. Phadke, O. A. Chow, and K. G. Blumenthal, “Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module,” The Journal of Allergy and Clinical Immunology: In Practice, vol. 7, no. 2, pp. 633–640, 2019.

[5] H. Bocquet, M. Bagot, and J. C. Roujeau, “Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS),” Seminars in Cutaneous Medicine and Surgery, vol. 15, no. 4, pp. 250–257, 1996.

[6] M. Eshki, L. Allanore, P. Musette et al., “Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure,” Archives of Dermatology, vol. 145, no. 1, pp. 67–72, 2009.

[7] S. Tas and T. Simonart, “Drug rash with eosinophilia and systemic symptoms (DRESS syndrome),” Acta Clinica Belgica, vol. 54, no. 4, pp. 197–200, 1999.

[8] Y. Kano, T. Ishida, K. Hirahara, and T. Shiohara, “Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome,” Medical Clinics of North America, vol. 94, no. 4, pp. 743–759, 2010.

[9] Z. Husain, B. Y. Reddy, and R. A. Schwartz, “DRESS syndrome part 1. Clinical perspectives,” Journal of the American Academy of Dermatology, vol. 68, no. 5, p. 693, 2013.

[10] S. Hassan, S. Hassan, R. Wetz, and E. Zouein, “Allopurinol causing drug rash with eosinophilia and systemic symptoms syndrome: a challenging diagnosis,” International Journal of General Medicine, vol. 4, pp. 789–792, 2011.

[11] A. Pannu and A. Saroch, “Diagnostic criteria for drug rash and eosinophilia with systemic symptoms,” Journal of Family Medicine and Primary Care, vol. 6, no. 3, pp. 693–694, 2017.

[12] D.-H. Kim and Y.-I. Koh, “Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome,” Allergy, Asthma & Immunology Research, vol. 6, no. 3, pp. 216–221, 2014.

[13] P. Ichai, A. Laurent-Bellue, F. Saliba et al., “Acute liver failure/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors,” Transplantation, vol. 101, no. 8, pp. 1830–1837, 2017.

[14] P. Harrison, J. Wendon, and R. Williams, “Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure,” Hepatology, vol. 23, no. 5, pp. 1067–1072, 1996.

[15] J. G. Stine and J. H. Lewis, “Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review,” Expert Review of Gastroenterology & Hepatology, vol. 10, no. 4, pp. 517–536, 2015.

[16] W. M. Lee, L. S. Hynan, L. Rossaro et al., “Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure,” Gastroenterology, vol. 137, no. 3, pp. 856–864, 2009.